NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With MM

NCT04772989: Phase 1: A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in participants with advanced malignancies.

Sponsor

Arcus Biosciences, Inc

Multiple Locations

---

ClinicalTrials.gov Identifier: NCT04772989

Official Title: A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies

First Posted : February 26, 2021